Insights On Partnering

  1. Incorporating The Patient Voice To Improve Ulcerative Colitis Recruitment
    3/11/2019

    Dr. Joan Meyer, Covance Executive Director of Strategy & Planning for Inflammation, Infectious Diseases and General Medicine, discusses her team’s efforts to better understand patients’ opinions about inflammatory bowel disease trials and develop patient-centered clinical strategies to improve study recruitment.

  2. Advancing A Diabetes Multi-Registration Program
    3/11/2019

    A large pharmaceutical company asked Covance to support their studies for a diabetes Phase III program specifically to register a drug to treat Type 2 Diabetes. Read how Covance utilized its rich central laboratory services database and helped the sponsor achieve first patient in (FPI) ahead of schedule for all studies in the program and beat historical industry performance across a number of key metrics.

  3. Optimizing Protocol Design And Enhancing Patient Enrollment
    3/8/2019

    An emerging biopharmaceutical company was designing a Phase II trial in patients who had Type 2 Diabetes, Stage 3 chronic kidney disease (CKD) and macroalbuminuria. They were uncertain about how to balance the selection of the right patients for their trial endpoints with the ability to achieve rapid subject recruitment. Read how LabCorp de-identified clinical laboratory data helped evaluate the protocol feasibility and the overall design of the study while also making an adjustment in eligibility criteria was forecast to double the eligible patient pool – without impacting study endpoints.

  4. Closed Loop Technology And Integrated Expertise Mitigates Risk
    3/4/2019

    Discover how Almac helped one pharmaceutical company streamline processes and remove risk from their multiple clinical trial applications while maintaining data integrity with One Unified Clinical Trial Supply Solution.

  5. How A Product NDC Change Could Impact Your Rare Disease Patient Base
    2/28/2019

    In the Rare Disease space, a product NDC may change for any of several reasons. It’s imperative to think through the potential impact that a product NDC change may have on your established patient population. Here are a few things to consider that could reduce potential therapy gaps for patients when an NDC change is imminent.

  6. NIH Rare Disease Day: Research Brings Hope
    2/28/2019

    National Institutes of Health (NIH) Clinical Center and National Center for Advancing Translational Sciences (NCATS) has hosted Rare Disease Day at the NIH to participate in the global observance since 2009. Updates from stakeholders regarding their achievements and current initiatives make it evident that the collaboration of patients and researchers is critical to continue to make advancements in rare disease treatment. Here are some key messages from the event.

  7. Digital Recruitment Solutions
    2/28/2019

    Whatever your goal may be, online marketing can be integrated into your strategy to help make recruitment a success this fall. Read on to learn how social media and text messaging programs can help support your traditional recruitment campaigns.

  8. Looking Beyond The Impossible For Rare Diseases
    2/28/2019

    The NORD Rare Disease Summit brings together thought leaders from the rare disease community every year. Shazia Ahmad, Director, Patient & Physician Services, United Biosource shares what he learned at this year’s summit.

  9. 5 Reasons Why Pharma Needs A Pharmacovigilance Partner
    2/28/2019

    Are you finding that developing the right systems and SOPs to support long-term pharmacovigilance activities is time consuming and costly? Realize how collaborating with an external partner for these services alleviate this burden along with other added benefits.

  10. A Strategic Partner, Or A Vendor Looking To You For The Answers?
    2/21/2019

    Any capable CRO can provide manpower and execute orders on behalf of a sponsor, no questions asked, with little stake or interest in the endeavor’s ultimate success. What you need is a strategic ally, a company that joins you, lockstep, in pursuing shared goals and greater outcomes. Not a vendor, but a partner.